13-LnHPO |
(9Z,11E,15Z)-13-Hydroperoxyoctadeca-9,11,15-trienoic acid |
ALA |
alpha-Linoleic acid |
ALT |
Advanced Lipid Technologies |
ARA |
Arachidonic acid |
AUCt |
Area under the (concentration-time) curve |
CFA |
Conjugated fatty acid |
Cmax
|
Maximum concentration |
DAG |
Diacylglycerol |
DHA |
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid (cervonic acid) |
DPA |
(7Z,10Z,13Z,16Z,19Z)-Docosa-7,10,13,16,19-pentaenoic acid (clupanodonic acid) |
DTrE |
(13Z,16Z,19Z)-Docosa-13,16,19-trienoic acid |
EE |
Ethyl esters |
EFA |
Essential fatty acid |
EPA |
(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoic acid (timnodonic acid) |
ETA |
(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoic acid |
ETE |
(11Z,14Z,17Z)-Icosa-11,14,17-trienoic acid (homo-alpha-linolenic acid) |
FA |
Fatty acid |
FFA |
Free fatty acid |
FMLP |
N-Formylmethionyl-leucyl-phenylalanine |
HDA |
(9Z)-12-Hydroxydodec-9-enoic acid |
HDL |
High-density lipoprotein |
HFA |
Hydroxy fatty acid |
HPA |
(6Z,9Z,12Z,15Z,18Z)-Henicosa-6,9,12,15,18-pentaenoic acid |
iAUCt |
Incremental area under the (concentration-time) curve |
LA |
Linoleic acid |
LC |
Long-chain |
LDL |
Low-density lipoprotein |
MAG |
Monoacylglycerol |
MCFA |
Medium-chain fatty acid |
MUFA |
Monounsaturated fatty acid |
PA |
Phosphatidic acid |
PC |
Phosphatidylcholine |
PE |
Phosphatidylethanolamine |
PG |
Phosphatidylglycerol |
PKC |
Protein kinase C |
PL |
Phospholipids |
PUFA |
Polyunsaturated fatty acid |
rTG |
Re-esterified TG |
SC401 |
DHA and EPA ethylesters + Advanced Lipid Technologies |
SCFA |
Short-chain fatty acid |
SDA |
Stearidonic acid |
SEDDS |
Self-emulsifying drug delivery system |
SLN |
Solid lipid nanoparticles |
SMEDS |
Self-microemulsifying delivery system |
SNEDDS |
Self-nanoemulsifying drug delivery system |
TG |
Triacylglycerol (Triacylglyceride, Triglyceride) |
VFA |
Volatile fatty acid |
VLCFA |
Very long-chain fatty acid |
WPI-GA |
Whey protein isolate-gum arabic (complex) |